Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may reveal if allergy treatment is effective

NCT ID NCT06876506

Knowledge-focused Sponsor: Hull University Teaching Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study aims to develop a blood test that measures B regulatory cells, which may indicate whether allergen immunotherapy (allergy shots) is successfully reducing allergic reactions. Researchers will study 80 adults with pollen or venom allergies who are starting routine allergy shots, along with a control group without allergies. Participants will give blood samples and fill out quality-of-life questionnaires to see if changes in these immune cells match improvements in allergy symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allergen specific immunotherapy (allergy shots)
What this could lead to
If successful, this could lead to a simple blood test that tells doctors whether allergy shots are working, helping personalize treatment.
What could go wrong
This is an early observational study, not a treatment trial. The blood test may not reliably predict treatment success, and results may not apply to all allergies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals Test cohort patients - selected from patients who meet eligibility criteria of the study, and who are starting routine allergen immunotherapy as part of their routine care outside of the study Allergen immunotherapy candidates to receive venom (bee/wasp), house dust mite or pollen immunotherapy only to be included in the study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Control cohort - Participants with: * No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms * Negative serological testing for specific IgE to pollens, house dust mite and insect venoms * Patients aged 18 years or older Test cohort: * Participants over the age of 18 years * Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms Exclusion Criteria: * Patients under the age of 18 years * Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom * Participants who are pregnant * Participants who cannot adequately understand verbal and / or written explanations given in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pollen allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dust Mite Allergy seasonal allergic rhinitis venom allergy Venom Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pollen allergy Venom allergy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hull Teaching Hospital NHS Trust

    RECRUITING

    Hull, East Yorkshire, HU3 2JZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.